Cardiovascular Health / Subcutaneous
Angiotensin II Receptor Antagonist Peptides (ARB-peptides)
Also known as Peptide ARBs, Angiotensin receptor blocker peptides
Peptide-based angiotensin II receptor blockers that regulate blood pressure and reduce cardiovascular inflammation through selective AT1 receptor antagonism.
What is Angiotensin II Receptor Antagonist Peptides (ARB-peptides) used for? Research has focused on reduces blood pressure in hypertension; decreases cardiovascular inflammation; improves endothelial function.
Compare with other peptides studied forimmune support
Angiotensin II Receptor Antagonist Peptides (ARB-peptides) injection at a glance
Figures from the published research literature. Research use only.
- Dose range
- 100-300 mcg
- Route
- Subcutaneous
How often, when, and the dosing notes are in the dosing reference further down.
Work out your units in the free calculatorBeginner basics
Plain-English guide to Angiotensin II Receptor Antagonist Peptides (ARB-peptides)
- What it does
- This peptide works like a brake on a specific receptor in your blood vessels that controls blood pressure and inflammation. Researchers study it to help manage high blood pressure and reduce strain on the heart and kidneys.
- Typical dose
- Researchers typically start at 100 micrograms and may go up to 300 micrograms, injected under the skin once or twice daily.
- When to inject
- Inject in the morning and/or evening at the same times each day to keep levels consistent in your body.
- Storage
- Keep the dry powder in a cool, dark place until you mix it. Once mixed with liquid, store in the refrigerator and use within the time specified by your supplier.
- Beginner tip
- Start at the lower dose (100 mcg) and only increase if needed-this gives your body time to adjust and helps you notice how it affects you.
Research status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research areas
- Reduces blood pressure in hypertension
- Decreases cardiovascular inflammation
- Improves endothelial function
- Reduces proteinuria in kidney disease
- Lowers risk of heart failure progression
- Decreases aldosterone-mediated sodium retention
- Reduces arterial stiffness
Side effects
| Effect | How often | Severity |
|---|---|---|
| Hypotension (low blood pressure)May occur especially during initial dosing or dose escalation. Symptoms include dizziness, lightheadedness, or syncope. Manage by rising slowly from sitting or lying positions, increasing fluid intake, and monitoring blood pressure regularly. Inform your healthcare provider if symptoms persist or worsen. | Common | Mild |
| Hyperkalemia (elevated potassium)ARB-peptides reduce aldosterone, which can increase serum potassium levels. Risk is higher in patients with renal impairment, diabetes, or concurrent use of ACE inhibitors, NSAIDs, or potassium supplements. Requires periodic serum potassium monitoring. Contact your healthcare provider immediately if you experience muscle weakness, palpitations, or irregular heartbeat. | Uncommon | Serious |
| Renal function changesMay cause transient increases in serum creatinine or decreases in glomerular filtration rate (GFR), particularly in patients with pre-existing renal disease or severe bilateral renal artery stenosis. Requires baseline and periodic monitoring of serum creatinine and eGFR. Discontinue if creatinine rises >30% from baseline. | Uncommon | Moderate |
| Local injection site reactionsRedness, swelling, bruising, or mild pain at the injection site. Usually resolves within 24-48 hours. Prevent by rotating injection sites, using proper injection technique, and allowing the solution to reach room temperature before injection. Apply ice if swelling occurs. | Uncommon | Mild |
| Lipodystrophy (fat loss or thickening at injection sites)Localized loss or accumulation of subcutaneous fat at frequently used injection sites. Prevent by systematically rotating injection sites with each dose and spacing injections at least 1 inch apart. This is cosmetic and typically reversible if site rotation is implemented. | Uncommon | Mild |
| Dizziness or lightheadednessOften related to blood pressure reduction. Manage by rising slowly from sitting or lying positions, staying well-hydrated, and avoiding rapid position changes. Usually resolves within 1-2 weeks as the body adjusts. | Common | Mild |
| Fatigue or weaknessMay occur during initial dosing or dose escalation. Usually self-resolving within 1-2 weeks. If persistent, contact your healthcare provider to rule out hyperkalemia or other causes. | Uncommon | Mild |
| CoughUnlike ACE inhibitors, ARB-peptides should not significantly increase bradykinin levels, so cough is rare. If cough develops, consult your healthcare provider to rule out other causes. | Rare | Mild |
| AngioedemaRare but serious allergic reaction causing swelling of the face, lips, tongue, or throat. Seek immediate emergency medical attention if you experience difficulty breathing, swallowing, or speaking, or if facial swelling develops. Discontinue immediately and do not rechallenge. | Rare | Serious |
| Allergic reaction (rash, urticaria)Skin rash or hives may indicate hypersensitivity to the peptide or excipients. Discontinue use and contact your healthcare provider. Do not rechallenge without medical supervision. | Rare | Moderate |
Dosing reference
Dose scale from the research
- Starting
- 100 mcg
- Typical
- 150 mcg
- Upper end
- 300 mcg
| Parameter | Value |
|---|---|
| Dose range | 100-300 mcg |
Frequency, timing and route are for members | |
Checked October 2026
Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution guide
- Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
- Do not shake the vial vigorously; gentle swirling prevents peptide degradation
- Discard immediately if the solution appears cloudy, discolored, or contains visible particles
- Use within 30 days of reconstitution when stored at 2-8°C
- Do not freeze the reconstituted solution; freezing may denature the peptide
- Use the PeptideVolt reconstitution calculator for your exact concentration
Worked example
With 5 mg in the vial, the water you add changes the draw. Mixed with 1 mL that is 5,000 mcg per mL, so on a U-100 syringe 100 mcg is 2 units and 300 mcg is 6 units. Mixed with 2 mL it is 2,500 mcg per mL, so 100 mcg is 4 units and 300 mcg is 12 units.
Molecular and pharmacological data
ARB-peptides function as selective antagonists of the angiotensin II type 1 (AT1) receptor, blocking the binding of angiotensin II and preventing downstream signaling that leads to vasoconstriction, aldosterone release, and inflammatory responses. By inhibiting AT1 receptor activation, these peptides reduce blood pressure, decrease sodium and water retention, and suppress pro-inflammatory and pro-fibrotic pathways in the cardiovascular and renal systems. This mechanism is similar to small-molecule ARBs but may offer improved selectivity, reduced off-target effects, and potentially enhanced tissue penetration depending on the specific peptide sequence and formulation.
Keep a log of your Angiotensin II Receptor Antagonist Peptides (ARB-peptides) research
Free account. No credit card required.
Research citations
5 sources
Siragy HM, Carey RM. (2003). The subtype 2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3',5'-monophosphate and AT1 receptor-mediated prostaglandin production in conscious rats. Journal of Hypertension. 21(10):1838-1846. PMID: 14508185
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. (2000). International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological Reviews. 52(3):415-472. PMID: 10962866
Steckelings UM, Kaschina E, Unger T. (2005). The AT2 receptor: a matter of love and hate. Journal of the American Society of Nephrology. 16(6):1504-1508. PMID: 15888560
Patel VB, Mori J, McLean BA, Basu R, Das SK, Ramprasath T, Parajuli N, Penninger JM, Grant MB, Lopaschuk GD, Oudit GY. (2016). ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes. 65(1):85-95. PMID: 26395741
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. (2005). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on cardiac angiotensin-converting enzyme 2. Circulation. 111(20):2605-2610. PMID: 15897343
Related: Cardiovascular Health
All Cardiovascular Health peptidesBrowse the research library
147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.
View all peptidesStay updated on Angiotensin II Receptor Antagonist Peptides (ARB-peptides) research
A weekly digest of new peptide research, stack guides and site updates.
Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Angiotensin II Receptor Antagonist Peptides (ARB-peptides) is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.